Murillo Raúl, Herrero Rolando, Sierra Mónica S, Forman David
Section of Early Detection and Prevention, Prevention and Implementation Group, International Agency for Research on Cancer, Lyon, France.
Section of Early Detection and Prevention, Prevention and Implementation Group, International Agency for Research on Cancer, Lyon, France.
Cancer Epidemiol. 2016 Sep;44 Suppl 1:S121-S130. doi: 10.1016/j.canep.2016.07.015.
More than 20 years after cytology-based screening was introduced in Central and South America (CSA), cervical cancer remains a leading cause of cancer incidence and mortality in the region. Although several population-based registries exist in the region, few comprehensive analyses have been conducted to describe the status of cervical cancer control.
Population-based data from cancer registries in 13 countries and mortality data from 18 countries in CSA were analyzed. Standardized incidence and mortality rates were estimated and time trend analysis performed when information was available. In addition, a search of available data on HPV vaccination and cervical cancer screening was carried out.
Cervical cancer incidence and mortality have decreased in some CSA countries, with an annual percentage change from -4.2 to -6.7 for incidence and -0.2 to -8.3 for mortality. In total, seven countries have age-standardized mortality rates over 10 per 100,000 women, generally corresponding to those with the lowest income levels. All countries have implemented screening programs with different extents of coverage and levels of organization. To date, nine countries have introduced HPV vaccination in national immunization programs.
Despite incidence declines observed in some countries, cervical cancer mortality remained almost stable in most countries in the region. Decreases in mortality trends in Chile and Costa Rica are probably the result of early detection programs. Better organized programs might favor greater impact on cancer incidence and mortality, but technological developments offer more suitable opportunities for prevention and alternative approaches for screening of precancerous lesions.
在中美洲和南美洲(CSA)引入基于细胞学的筛查20多年后,宫颈癌仍然是该地区癌症发病率和死亡率的主要原因。尽管该地区存在多个基于人群的登记处,但很少有进行全面分析来描述宫颈癌控制的现状。
分析了来自CSA 13个国家癌症登记处的基于人群的数据以及18个国家的死亡率数据。在有可用信息时,估计标准化发病率和死亡率并进行时间趋势分析。此外,还搜索了关于HPV疫苗接种和宫颈癌筛查的可用数据。
一些CSA国家的宫颈癌发病率和死亡率有所下降,发病率的年百分比变化为-4.2至-6.7,死亡率为-0.2至-8.3。总共有七个国家每10万名女性的年龄标准化死亡率超过10,这通常与收入水平最低的国家相对应。所有国家都实施了覆盖范围和组织水平不同的筛查计划。迄今为止,有九个国家在国家免疫计划中引入了HPV疫苗接种。
尽管一些国家的发病率有所下降,但该地区大多数国家的宫颈癌死亡率几乎保持稳定。智利和哥斯达黎加死亡率趋势的下降可能是早期检测计划的结果。组织更完善的计划可能更有利于对癌症发病率和死亡率产生更大影响,但技术发展为预防提供了更合适的机会以及筛查癌前病变的替代方法。